|
|
|
|
We conducted this study to find out the effectiveness of treatment as well as some prognostic factors when using R-GDP (Rituximab- Gemcitabine, Dexamethasone, and Cisplatin) regimen to treat transplant-ineligible relapsed non-Hodgkin B-cell lymphoma patients. 49 patients diagnosed with relapsed non-Hodgkin B-cell lymphoma treated with R-GDP (Rituximab- Gemcitabine, Dexamethasone, and Cisplatin) regimen were retrospectively analyzed. Patients who subsequently underwent autologous stem cell transplantation were excluded. After 2 cycles, ORR was 71.4%: CR: 12 patients (24.5%), PR: 23 patients (46.9%). 14 patients (28.6%) who did not achieve at least PR would be treated with another regimen. After 6 cycles, CR was 38.8% (19 patients). Median OS and PFS were 36 and 32 months; respectively. The 5-year rates were 36.4 % and 18.1% for OS and PFS; respectively. No serious side effects were reported. Neutrophilia and thrombocytopenia were grade 3, and grade 2; respectively. Univariate and multivariate analysis showed that LDH ≥237 U/L was an independent adverse prognostic factor for OS (P=0.003, HR: 6.256, 95% CI: 1.900- 20.602), BCL6 positive and LDH ≥ 237 U/L were an independent adverse prognostic factors for PFS (P=0.047, HR: 3.651, 95% CI: 1.020- 13.074; P=0.049; HR: 3.707, 95% CI: 1.004- 13.678; respectively). R-GDP is effective and has less toxicity in the treatment of transplant-ineligible relapsed non-Hodgkin B cell lymphoma patients, LDH ≥237 U/L is an independent adverse prognostic factor for OS and PFS, while BCL6 positive are independent adverse prognostic factors for PFS.
|
||||||||
